Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States.
| Revenue (Most Recent Fiscal Year) | $23.68M |
| Net Income (Most Recent Fiscal Year) | $-318.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 15.38 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 14.73 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -279.31% |
| Net Margin (Trailing 12 Months) | -279.31% |
| Return on Equity (Trailing 12 Months) | -160.60% |
| Return on Assets (Trailing 12 Months) | -49.58% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.64 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.42 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 2.78 |
| Inventory Turnover (Trailing 12 Months) | 0.43 |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.38 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.70 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.72 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.61 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 86.92M |
| Free Float | 83.35M |
| Market Capitalization | $1.72B |
| Average Volume (Last 20 Days) | 2.29M |
| Beta (Past 60 Months) | 0.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.10% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |